Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies-Reference-Cited by-同舟云学术

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies

Published:2017-11 Issue:5 Volume:140 Page:1464-1466.e4
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Albers Frank C.,Price Robert G.,Smith Steven G.,Yancey Steven W.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference6 articles.

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. Available at: http://www.ginasthma.org. Accessed June 2017.

2. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

3. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial;Pavord;Lancet,2012

4. Mepolizumab treatment in patients with severe eosinophilic asthma;Ortega;N Engl J Med,2014

5. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma;Bel;N Engl J Med,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy;BMC Pulmonary Medicine;2024-03-21

2. Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities;Journal of Leukocyte Biology;2024-03-08

3. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy;2023-08-29

4. Organization of biological therapy for patients with severe eosinophilic bronchial asthma in the Krasnoyarsk region;PULMONOLOGIYA;2023-02-11

5. Anti-IL-5 therapies for asthma;Cochrane Database of Systematic Reviews;2022-07-12